JP Morgan Chase
RETA

JP Morgan Chase’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

JP Morgan Chase’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-65,600
Closed -$5.27M – 5962
2019
Q3 		$5.27M Buy
65,600
+35,600
+119% +$3.02M ﹤0.01% 2659
2019
Q2 		$2.75M Buy
+30,000
New +$2.59M ﹤0.01% 3158

Other funds holding RETA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's RETA Position: Q3 2023 in Review

JP Morgan Chase sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 206,223 shares — an estimated $21M sold.

JP Morgan Chase first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $21M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • JP Morgan Chase reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • JP Morgan Chase sold 206,223 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $21M.
  • JP Morgan Chase first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
  • JP Morgan Chase's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $21M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.